Hopstem Biotech closes first tranche of Series C for iPSC neural cell therapy
What's the deal? Hopstem Biotech announced the first closing of a Series C financing on 10 August 2026. The financing includes new investors Tasly CapitalDealroom has a profile for this one. Try Dealroom →, Haibang Investment and Guangzhou Health Industry Investment, alongside existing backer Longmen CapitalDealroom has a profile for this one. Try Dealroom →. The amount was not disclosed.
What's next? The company plans to use the financing to accelerate clinical development of hNPC01, an iPSC-derived forebrain neural progenitor cell therapy, across multiple indications and advance commercial manufacturing.
Why now? The announcement follows positive Phase I results in chronic ischaemic stroke and regulatory milestones for hNPC01, including Regenerative Medicine Advanced Therapy and Fast Track designations from the U.S. Food and Drug Administration. The FDA has also cleared two new investigational new drug applications and granted Fast Track status for chronic motor dysfunction linked to haemorrhagic stroke and traumatic brain injury.
Read more: GlobeNewswire
Image credit: NIH-NCATS
